



COMPANY OVERVIEW

Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.

RECENT NEWS

Amarantus to Present at LD Micro and The Reg A Conference

May 24 2018, 11:00 AM EDT

Amarantus Retains Weild & Co. to Advise on JOBS Act Funding

May 22 2018, 6:00 AM EDT

MANF Therapeutics Announces Publication in Society for Neuroscience eNeuro Journal of Human Ocular Distribution and Animal Photoreceptor Protection Data for MANF

May 21 2018, 8:40 AM EDT

STOCK OVERVIEW

Symbol	AMBS
Exchange	OTCPink
Shares OS	68,272,000
Market Cap	\$3.22M
Last Price	\$0.0472
52-Week Range	\$0.01 - \$0.2085
Fiscal Year End	December 31

INVESTOR RELATIONS

American Capital Ventures, Inc.
Howard Gostfrand
President
T: 305-918-7000
F: 305-468-6165
hg@amcapventures.com

MANAGEMENT TEAM

Gerald E. Commissiong

President & Chief Executive Officer

Barney Monte

Interim Chief Operating Officer and Chief Financial Officer

Brian E. Harvey, MD, PhD

Chief Regulatory Advisor

Elise Brownell, Ph.D.

Senior Vice President of Operations and Project Management

John W. Commissiong, PhD

Chief Scientific Officer

Paula Trzepacz, MD

Chief Medical Advisor to Elto Pharma

Dr. Richard Kagan

Chief Medical Advisor to Cutanogen Corporation

Michael T. Ropacki, PhD

Chief Medical Advisor - Alzheimer's Blood Diagnostic LymPro Test®

AMARANTUS BIOSCIENCE HOLDINGS, INC.

110 Wall Street
New York, NY 10005
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.